NCT02689778View on ClinicalTrials.gov

Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Diabetic NephropathyAlbuminuria

Interventions

DRUG

Pirfenidone

Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.

DRUG

Placebo

Identical tablets without active substance

Trial Locations (1)

14080

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ), Mexico City

All Listed Sponsors

collaborator

Grupo Medifarma, S. A. de C. V.

INDUSTRY

lead

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

NCT02689778 - Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter